LA JOLLA, Calif., July 15, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial results for the third quarter ending May 31, 2019 and provided a corporate update.
News
Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option
LA JOLLA, Calif., June 25, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the ?Company? or ?Artelo Biosciences?), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the en… […]
News
Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
LA JOLLA, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at th… […]
News
Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine
LA JOLLA, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that two research studies condu… […]
